Abstract:Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules. The interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs), largely contributing to the maintenance of immune homeostasis that prevents dysregulated immunity and harmful immune responses. However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression. Blockade of PD-1/PD-L1 by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity, achieving remarkable success in cancer therapy. Therefore, the regulatory mechanisms of PD-1/PD-L1 in cancers have attracted an increasing attention. This article aims to provide a comprehensive review of the roles of the PD-1/PD-L1 signaling in human autoimmune diseases and cancers. We summarize all aspects of regulatory mechanisms underlying the expression and activity of PD-1 and PD-L1 in cancers, including genetic, epigenetic, post-transcriptional and post-translational regulatory mechanisms. In addition, we further summarize the progress in clinical research on the antitumor effects of targeting PD-1/PD-L1 antibodies alone and in combination with other therapeutic approaches, providing new strategies for finding new tumor markers and developing combined therapeutic approaches.

Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies

Programmed Death 1/programmed Death Ligand 1 Signaling Pathway in Tumor Immunotherapy: an Update

The role of PD-1 signaling in health and immune-related diseases

Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies

PD-1 regulation in immune homeostasis and immunotherapy

Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms

PD-1/PD-L1 pathway: current researches in cancer.

PD-1 and PD-1 ligands: from discovery to clinical application

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Macrophage involvement in idiopathic inflammatory myopathy: pathogenic mechanisms and therapeutic prospects

The diverse functions of the PD1 inhibitory pathway

The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review

Inflammasomes/IL-1 pathways in myeloid cells modulate PD-1/PD-L1 checkpoint molecules

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?

Regulatory mechanisms of PD-1/PD-L1 in cancers

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Programmed death protein 1 is essential for maintaining the anti-inflammatory function of infiltrating regulatory T cells in a murine spinal cord injury model

[Progress in Research on Tumor Immune PD-1/PD-L1 Signaling Pathway in Malignant Bone Tumors].

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade